{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T18:01:32Z","timestamp":1692554492896},"reference-count":14,"publisher":"Medical Association of Nippon Medical School","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nippon Med Sch"],"published-print":{"date-parts":[[2016]]},"DOI":"10.1272\/jnms.83.167","type":"journal-article","created":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T22:14:04Z","timestamp":1475014444000},"page":"167-171","source":"Crossref","is-referenced-by-count":3,"title":["Vigabatrin Therapy for Infantile Spasms in a Case of Cardiofaciocutaneous Syndrome with Cardiac Hypertrophy Developing during Adrenocorticotropic Hormone Treatment"],"prefix":"10.1272","volume":"83","author":[{"given":"Takayuki","family":"Hatori","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Jichi Medical University Saitama Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Jichi Medical University Saitama Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Jichi Medical University Saitama Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Hirakubo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Jichi Medical University Saitama Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Nonaka","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Jichi Medical University Saitama Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ko","family":"Ichihashi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Jichi Medical University Saitama Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"21","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Niihori T, Aoki Y, Narumi Y, Neri G, Cav\u00e9 H, Verloes A, Okamoto N, Hennekam RC, Gillessen-Kaesbach G, Wieczorek D, Kavamura MI, Kurosawa K, Ohashi H, Wilson L, Heron D, Bonneau D, Corona G, Kaname T, Naritomi K, Baumann C, Matsumoto N, Kato K, Kure S, Matsubara Y: Germline <i>KRAS<\/i> and <i>BRAF<\/i> mutations in cardio-facio-cutaneous syndrome. Nat Genet 2006; 38: 294-296.","DOI":"10.1038\/ng1749"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, Cruz MS, McCormick F, Rauen KA: Germlime mutations in gene within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 2006; 311: 1287-1290.","DOI":"10.1126\/science.1124642"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Yoon G, Rosenberg J, Blaser S, Rauen KA: Neurological complications of cardio-facio-cutaneous syndrome. Dev Med Child Neurol 2007; 49: 894-899.","DOI":"10.1111\/j.1469-8749.2007.00894.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Armour CM, Allanson JE: Further delineation of cardio-facio-cutaneous syndrome: clinical features of 38 individuals with proven mutations. J Med Genet 2008; 45: 249-254.","DOI":"10.1136\/jmg.2007.054460"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Pellock JM, Hrachovy R, Shinnar S, Baram TZ, Bettis D, Dlugos DJ, Gaillard WD, Gibson PA, Holmes GL, Nordl DR, O&apos;Dell C, Shields WD, Trevathan E, Wheless JW: Infantile spasms: A U.S. consensus report. Epilepsia 2010; 51: 2175-2189.","DOI":"10.1111\/j.1528-1167.2010.02657.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Abe Y, Aoki Y, Kuriyama S, Kawame H, Okamoto N, Kurosawa K, Ohashi H, Mizuno S, Ogata T, Kure S, Niihori T, Matsubara Y: Prevalence and clinical features of Costello syndrome and cardio-facio-cutaneous syndrome in Japan findings from a nationwide epidemiological survey. Am J Med Gent A 2012; 158A: 1083-1094.","DOI":"10.1002\/ajmg.a.35292"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Aizaki K, Sugai K, Saito Y, Nakagawa E, Sasaki M, Aoki Y, Matsubara Y: Cardio-facio-cutaneous syndrome with infantile spasms and delayed myelination. Brain Dev 2011; 33: 166-169.","DOI":"10.1016\/j.braindev.2010.03.008"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Adachi M, Abe Y, Aoki Y, Matsubara Y: Epilepsy in RAS\/MAPK syndrome: two cases of cardio-facio-cutaneous syndrome with epileptic encephalopathy and literature review. Seizure 2012; 21: 55-60.","DOI":"10.1016\/j.seizure.2011.07.013"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ben-Menachem E: Mechanism of action of vigabatrin: correcting misperceptions. Acta Neurol Scand Suppl 2011; 192: 5-15.","DOI":"10.1111\/j.1600-0404.2011.01596.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Zhang B, McDaniel SS, Rensing NR, Wong M: Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex. PLoS One 2013; 8: e57445.","DOI":"10.1371\/journal.pone.0057445"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kondo Y, Okumura A, Watanabe K, Negoro T, Kato T, Kubota T, Hiroko K: Comparison of two low dose ACTH therapies for West syndrome: their efficacy and side effect. Brain Dev 2005; 27: 326-330.","DOI":"10.1016\/j.braindev.2004.09.003"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Wild JM, Chiron C, Ahn H, Baulac M, Bursztyn J, Gandolfo E, Goldberg I, Go\u00f1i FJ, Mercier F, Nordmann JP, Safran AB, Schiefer U, Perucca E: Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study. CNS Drugs 2009; 23: 965-982.","DOI":"10.2165\/11317650-000000000-00000"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Maguire MJ, Hemming K, Wild JM, Hutton JL, Marson AG: Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review. Epilepsia 2010; 51: 2423-2431.","DOI":"10.1111\/j.1528-1167.2010.02772.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Pellock JM: Balancing clinical benefits of vigabatrin with its associated risk of vision loss. Acta Neurol Scand Suppl 2011; 192: 83-91.","DOI":"10.1111\/j.1600-0404.2011.01603.x"}],"container-title":["Journal of Nippon Medical School"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/83\/4\/83_167\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T23:50:01Z","timestamp":1498348201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/83\/4\/83_167\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1272\/jnms.83.167","relation":{},"ISSN":["1345-4676","1347-3409"],"issn-type":[{"value":"1345-4676","type":"print"},{"value":"1347-3409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}